Leili Gao
Xizhimen South Street
Xizhimen, 100044, China
Xizhimen, 100044, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 39 publications
False Elevation of Parathyroid Hormone in a Patient With Lung Metastasis of Rectal Cancer After Immunotherapy: A Case Report and Literature Review.
Journal: Case reports in immunology
Published: December 13, 2025
A clinical prediction model for beta cell monogenetic diabetes in Chinese patients with early-onset type 2 diabetes.
Journal: Diabetes & metabolism
Published: November 07, 2025
Efficacy and safety of bofanglutide, a GLP-1 receptor agonist, in Chinese adults with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial.
Journal: Signal transduction and targeted therapy
Published: October 14, 2025
GZR18, a GLP-1 analog with once-weekly or bi-weekly dosing for body weight management: A randomized, placebo-controlled, phase 1b/2a trial.
Journal: Cell reports. Medicine
Published: September 23, 2025
Oral nonpeptide GLP-1 receptor agonist VCT220 for obesity treatment: a randomized, double-blind, phase II trial.
Journal: Signal transduction and targeted therapy
Published: September 19, 2025
Efficacy and safety of chiglitazar add-on to metformin in type 2 diabetes mellitus (RECAM study).
Journal: Diabetes, obesity & metabolism
Published: April 28, 2025
Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Journal: The lancet. Diabetes & endocrinology
Published: March 25, 2025
Intense simplified strategy for newly diagnosed type 2 diabetes in patients with severe hyperglycaemia: multicentre, open label, randomised trial.
Journal: BMJ (Clinical research ed.)
Published: October 15, 2024
Denosumab for Management of Hypercalcemia in Primary Hyperparathyroidism.
Journal: Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme
Published: October 11, 2024
Efficacy and safety of insulin degludec/insulin aspart biosimilar B01711 vs originator insulin degludec/insulin aspart in Chinese patients with type 2 diabetes inadequately controlled on basal or premixed insulin: A multicenter, randomized, open-label, phase 3 study.
Journal: Journal of diabetes investigation
Published: September 18, 2024
Efficacy and safety of insulin degludec biosimilar B01411 versus originator insulin degludec in Chinese patients with type 2 diabetes inadequately controlled on oral antidiabetic drugs: a multicenter, randomized, open-label, phase 3 study.
Journal: Current medical research and opinion
Published: September 05, 2024
Last Updated: 09/26/2026